Literature DB >> 17300746

Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis.

Antoine W T van Lieshout1, Calin Popa, Friederike Meyer-Wentrup, Heidi L Lemmers, Anton F Stalenhoef, Gosse J Adema, Piet L C M van Riel, Lambertus J van Tits, Timothy R D J Radstake.   

Abstract

CXCL16 acts as a scavenger receptor for oxLDL in its membrane-bound form and induces migration of activated T cells in its soluble form. Due to these properties, CXCL16 has been suggested to play a role in both atherosclerosis and rheumatoid arthritis (RA). Our aim was to evaluate the contribution of soluble CXCL16 to the scavenging of oxLDL and its potential as a marker for cardiovascular disease (CVD) in patients with RA. We found that circulating CXCL16 was not correlated with plasma oxLDL or ApoB and was not related to the presence of CVD in RA patients. Moreover, CXCL16 did not bind and scavenge oxLDL in an in vitro setting. These data suggest that binding of oxLDL by soluble CXCL16 does not play a role in atherosclerosis and, although confirmation in larger studies is needed, that circulating CXCL16 is not related to the presence of CVD in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300746     DOI: 10.1016/j.bbrc.2007.01.161

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors.

Authors:  Kuniaki Ota; Patrick Quint; Megan M Weivoda; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Bone       Date:  2013-07-25       Impact factor: 4.398

2.  Function modification of SR-PSOX by point mutations of basic amino acids.

Authors:  Weiwei Liu; Lan Yin; Chunxia Chen; Yalei Dai
Journal:  Lipids Health Dis       Date:  2011-04-15       Impact factor: 3.876

3.  The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.

Authors:  Yuji Shibata; Nobuaki Kobayashi; Takashi Sato; Kentaro Nakashima; Takeshi Kaneko
Journal:  Thorac Cancer       Date:  2020-03-12       Impact factor: 3.500

4.  Chemokines in Gestational Diabetes Mellitus.

Authors:  Hongying Liu; Aizhong Liu; Atipatsa C Kaminga; Judy McDonald; Shi Wu Wen; Xiongfeng Pan
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.